Evidence map›Paper›PMID 40529575›Full record

ArticleFrontiers in microbiology2025

Combining a rhesus cytomegalovirus/SIV vaccine with a neutralizing antibody to protect against SIV challenges in rhesus macaques.

Jessica Coppola, Mara Parren, Raiza Bastidas, Karen Saye, Jacqueline Malvin, Joseph G Jardine, Roxanne M Gilbride, Sohita Ojha, Shana Feltham, David Morrow and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Jessica CoppolaDepartment of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Mara ParrenDepartment of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Raiza BastidasDepartment of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Karen SayeDepartment of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Jacqueline MalvinDepartment of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Joseph G JardineDepartment of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Roxanne M GilbrideVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
Sohita OjhaVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
Shana FelthamVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
David MorrowVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
Aaron Barber-AxthelmVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
Rachele BochartVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
Randy FastAIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States.
Kelli OswaldAIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States.
Rebecca ShoemakerAIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, United States.
Louis J PickerVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.
Dennis R BurtonDepartment of Immunology and Microbiology, Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, IAVI Neutralizing Antibody Center, La Jolla, CA, United States.
Scott G HansenVaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Project 3: Determination of the minimal MHC-E-restricted SIV epitope targeting required for RhCMV/SIV vaccine-mediated SIV replication arrest efficacyP01AI174856 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Louis J. Picker · 2022 to 2026
$29.9M
Gates Foundation INV-037063NCI NIH HHS 75N91019D00024NIAID NIH HHS P01 AI174856NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011092
6 · The paper itself

Abstract

A vaccine is considered essential for controlling the HIV pandemic and ultimately eradicating AIDS. Neutralizing antibodies and MHC-E-restricted CD8+ T cells have shown the ability to protect against the simian counterpart of HIV, SIV, in rhesus macaques. In this study, we provide preliminary evidence that combining these orthogonal antiviral mechanisms can offer increased protection against SIV. Specifically, the replication arrest observed following vaccination with a rhesus cytomegalovirus (RhCMV/SIV)-based vaccine was enhanced by the presence of a passively administered neutralizing antibody at incompletely protective levels. This report encourages studies involving larger cohorts of macaques and alternative methods for administering neutralizing antibodies.

Indexed as

HIVneutralizing antibodiesnon-human primate (macaque)SIVT cellsvaccine

Identifiers

PMID40529575
PMCPMC12171355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.